A phase II study of high-dose celecoxib and metronomic 'low-dose' cyclophosphamide and methotrexate in patients with relapsed and refractory lymphoma

Hematology/ Oncology and Stem Cell Therapy

Volumn 3, Issue 1, 2010, Pages 13-17

  Bary, Naser Abd El ^a   Hashem, Tarek ^a   Metwally, Hasan ^a   Ghany, Ashraf Abd ^a   Mageed, Hager Abd El ^a  

^a MENOUFIA UNIVERSITY   (Egypt)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; CELECOXIB; CYCLOPHOSPHAMIDE; DIURETIC AGENT; METHOTREXATE;

ADULT; AGED; ANEMIA; ARTICLE; CANCER CHEMOTHERAPY; CARDIOTOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; CREATININE BLOOD LEVEL; DRUG ERUPTION; DRUG MEGADOSE; DRUG RESPONSE; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; EDEMA; FATIGUE; FEMALE; FOLLOW UP; HUMAN; LARGE CELL LYMPHOMA; LIVER TOXICITY; LOW DRUG DOSE; MALE; NAUSEA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; RELAPSE; SIDE EFFECT; STOMATITIS; THROMBOCYTOPENIA; WEAKNESS;

EID: 77953670019     PISSN: 16583876     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1658-3876(10)50051-7     Document Type: Article

References (11)

1. Feugier P, Van Hoof A, Sebban C, Solal-Celigny P, Bouabdallah R, Fermé C, Christian B, Lepage E, Tilly H, Morschhauser F, Gaulard P, Salles G, Bosly A, Gisselbrecht C, Reyes F, Coiffier B. Long-term results of the R-CHOP study in the treatment of eldderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol. 2005; 23: 4117-4126.
2. Philip T, Guglielmi C, Hagenbeek A, Somers R, Van der Lelie H, Bron D, Sonneveld P, Gisselbreccht C, Cahn JY, Harousseau JL. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-senssitive non-Hodgkin's lymphoma. N Engl J Med. 1995; 333:1540-1545.
3. Seshadri T, Kuruvilla J, Crump M, Keating A. Salvage Therapy for Relapsed/Refractory Diffuse Large B Cell Lymphoma. Biol Blood Marrow Transpplant 2008.14:259-267.
4. Dong X, Han ZC, Yang R. Angiogenesis and antiangiogenic therapy in hematologic malignancies. Crit Rev Oncol Hematol. 2007;62:105-18.
5. Koster A, Raemaekers JM. Angiogenesis in mallignant lymphoma. Curr Opin Oncol. 2005;17(6):611-6.
6. Kerbel RS, Kamen BA. The anti-angiogenic bassis of metronomic chemotherapy. Nat Rev Canccer. 2004;4:423-436.
7. Wang ES, Teruya-Feldstein J, Wu Y, Zhu Z, Hicklin DJ, Moore MA. Targeting autocrine and paracrine VEGF receptor pathways inhibiits human lymphoma xenografts in vivo. Blood. 2004;104(9):2893-902.
8. Wun T, McKnight H, Tuscano JM. Increased cyclooxygenase-2 (COX-2): a potential role in the pathogenesis of lymphoma. Leuk Res 2004. 28:179-90.
9. Buckstein R, Kerbel RS, Shaked Y, Nayar R, Foden C, Turner R, Lee CR, Taylor D, Zhang L, Man S, Baruchel S, Stempak D, Bertolini F, Crump M. High-Dose Celecoxib and Metronomic "Lowdose" Cyclophosphamide Is an Effective and Safe Therapy in Patients with Relapsed and Refractory Aggressive Histology Non Hodgkin's Lymphoma. Clin Cancer Res. 2006;12(17):5190-5198.
10. Cheson BC, Horning SJ, Coiffer B, Shipp MA, Fisher Ri, Connors JM, Lister AT, Vose J, Grillo-Lopez A, Hagenbeek A, Cabanillas F, Klippenssten D, Hiddemann W, Castellino R, Harris NL, Armitage JO, Carter W, Hoppe R, Canellos GP. Report of international workshop to standardize response criteria for Non-Hodgkins lymphomas. J Clin Oncol. 1999;17:1244-53.
11. Stopeck AT, Unger JM, Rimsza LM, Bellamy WT, Iannone M, Persky DO, Leblanc M, Fisher RI, Miller TP. Phase II trials of single agent bevacizzumab in patients with relapsed, aggressive non-Hodgkin's lymphoma (NHL): Southwest Oncology Group study S0108. Proc Am Soc Clin Oncol. 2005; 23:583.